Treatment of hypersomnias

Handbook of Sleep Disorders, Second Edition

Volumn , Issue , 2008, Pages 299-319

  Dyken, Mark E ^a   Yamada, Thoru ^a   Ali, Mohsin ^b  

^a UNIVERSITY OF IOWA   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85123325970     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (169)

1. American Academy of Sleep Medicine,. International Classification of Sleep Disorders: Diagnostic and Coding Manual. 2nd ed. Westchester: American Academy of Sleep Medicine, 2005:79-115.
2. Bremer F. Cerveau "isole" et physiologie du sommeil. C R Soc Biol (Paris) 1929; 102:1235.
3. Moruzzi G, Magoun HW. Brain stem reticular formation and activation of the EEG. Electro-encephalogr Clin Neurophysiol 1949; 1:455.
4. Jovet M. The role of monoamines and acetylcholine-containing neurons in the regulation of the sleep-waking cycle. Ergebn Physiol 1972; 64:165.
5. Sherin JE, Elmquist JK, Torrealba F, et al. Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat. J Neurosci 1998; 18:4705-4721.
6. Aston-Jones G, Chiang C, Alexinsky T. Discharge of noradrenergic locus coeruleus neurons in behaving rats and monkeys suggests a role in vigilance. Prog Brain Res 1991; 88:501-520.
7. Woolf NJ, Butcher LL. Cholinergic systems in the rat brain: III. Projections from the pontomesencephalic tegmentum to the thalamus, tectum, basal ganglia, and basal forebrain. Brain Res Bull 1986; 16:603-637.
8. Dyken ME, Yamada T. Narcolepsy and disorders of excessive somnolence. In: Ballard RD, Lee-Chiong TL Jr, eds. Primary Care: Clinics in Office Practice. Philadelphia: Elsevier Saunders, 2005:389-413.
9. Saper CB, Chou TC, Scammel TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 2001; 24:726-731.
10. Von Economo C. Encephalitis Lethargica: Its Sequelae and Treatment. London: Oxford University Press, 1931.
11. Sherin JE, Shiromani PJ, McCarley RW, et al. Activation of ventrolateral preoptic neurons during sleep. Science 1996; 271:216-219.
12. Steininger T, Gong H, McGinty D, et al. Subregional organization of preoptic area/anterior hypothalamic projections to arousal-related monoaminergic cell groups. J Comp Neurol 2001; 429:638-653.
13. Gritti I, Mariotti M, Mancia M. Gabaergic and cholinergic basal forebrain and preoptic-anterior hypothalamic projections to the mediodorsal nucleus of the thalamus of the cat. Neuroscience 1998; 85:149-178.
14. Nitz D, Siegel JM. GABA release in the dorsal raphe nucleus. Role in the control of REM sleep. Am J Physiol 1997; 273:R451-R455.
15. Nitz D, Siegel JM. GABA release in the locus coeruleus as a function of sleep/wake state. Neuroscience 1997; 78:795-801.
16. Steriade M, Domich L, Oakson G, et al. The deafferented reticular thalamic nucleus generates spindle rhythmicity. J Neurophysiol 1987; 57:260-273.
17. Ricardo JA, Koh ET. Anatomical evidence of direct projections from the nucleus of the solitary tract to the hypothalamus, amygdala, and other forebrain structures in the rat. Brain Res 1978; 153:1.
18. Markand ON, Dyken ML. Sleep abnormalities in patients with brain stem lesions. Neurology 1976; 26:769.
19. McGinty D, Harper R. Dorsal raphe neurons: depression of firing during sleep in cats. Brain Res 1976; 101:569-575.
20. Littner M, Johnson SF, McCall MV, et al. Standards of Practice Committee. Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep 2001; 24(4):451-466.
21. Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007; 30:1705-1711.
22. Doyle JB, Daniels LE. Symptomatic treatment for narcolepsy. JAMA 1931; 96:1370-1372.
23. Prinzmetal M, Bloomberg W. The use of benzedrine for the treatment of narcolepsy. JAMA 1935; 105:2051-2054.
24. Alles GA. The comparative physiological actions of d 1-beta-phenylisopropylamines: pressor effects and toxicity. J Pharmacol Exp Ther 1933; 47:339-354.
25. Nishino S, Mao J, Sampathkumaran R, et al. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online 1998; 1:49-61.
26. Afifi AK, Bergman RA. Reticular formation, wakefulness, and sleep. In: Afifi AK, Bergman RA, eds. Functional Neuroanatomy: Text and Atlas. 2nd ed. New York: McGraw-Hill Medical, 2005:398-406.
27. Kaelber WW, Afifi AK. Nigro-amygdaloid fiber connections in the cat. Am J Anat 1977; 148:129-135.
28. Nissbrandt N, Engberg G, Pileblad E. The effects of GBR 12909, a dopamine re-uptake inhibitor, on monoaminergic neurotransmission in rat striatum, limbic forebrain, cortical hemispheres, and substantia nigra. Naunyn Schmiedebergs Arch Pharmacol 1991; 344:16-28.
29. Kuczenski R, Segal DS. Neurochemistry of amphetamine. In: Cho AD, Segel DS, eds. Psychopharmacology, Toxicology, and Abuse. San Diego: Academic Press, 1994:81-113.
30. Sulzer D, Chen TK, Lau YY, et al. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 1995; 15:4102-4108.
31. Gonzalez AM, Walther D, Pazos A, et al. Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile. Brain Res Mol Brain Res 1994; 22:219-226.
32. Kanbayashi T, Nishino S, Honda K, et al. Differential effects of D- and L-amphetamine isomers on dopminergic transmission: implication for the control of alertness in canine narcolepsy. Sleep Res 1997; 26:383.
33. Fujimori M, Himwich HE. Electroencephalographic analyses of amphetamine and its methoxy derivatives with reference to their sites of EEG alerting in the rabbit brain. Int J Neuropharmacol 1969; 8:601-613.
34. Mitler MM, Erman M, Hajdukovic R. The treatment of excessive somnolence with stimulant drugs. Sleep 1993; 16:203-206.
35. Seiden L, Sabol KE, Ricaurte GA. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 1993; 32:639-667.
36. Virmani A, Gaetani F, Imam S, et al. The protective role of L-carnitine against neurotoxicity evoked by drug of abuse, methamphetamine, could be related to mitochondrial dysfunction. Ann N Y Acad Sci 2002; 965:225-232.
37. Mitler MM, Hajdukovic RM. Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. Sleep 1991; 14:218-220.
38. Nishino S, Mignot E. Wake-promoting medications: basic mechanisms and pharmacology. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 4th ed. Philadelphia: Elsevier Saunders, 2005:468-483.
39. Parkes JD. Central nervous system stimulant drugs. In: Thorpy M, ed. Handbook of Sleep Disorders. New York: Marcel Dekker, 1990:755-778.
40. Yoss RE, Daly DD. Treatment of narcolepsy with Ritalin. Neurology 1959; 9:171-173.
41. Honda Y, Hishakawa Y, Takahashi Y. Long-term treatment of narcolepsy with methylphenidate (Ritalin). Curr Ther Res Clin Exp 1979; 25:288-298.
42. Klein RG, Mannuzza S. Hyperactive boys almost grown up. III. Methylphenidate effects on ultimate height. Arch Gen Psychiatry 1988; 45:1131-1134.
43. Honda Y, Hishikawa Y. Effectivenes of pemoline in narcolepsy. Sleep Res 1970; 8:192.
44. Nehra A, Mullick F, Ishak KG, et al. Pemoline-associated hepatic injury. Gastroenterology 1990; 99:1517-1519.
45. Robertson P, DeCory HH, Madan A, et al. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos 2000; 28:664-671.
46. Bastuji H, Jovet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12:695-700.
47. Saper CB, Scammell TE. Modafinil: a drug in search of a mechanism. Sleep 2004; 27:11-12.
48. Duteil J, Rambert FA, Pessonnier J, et al. Central a 1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil: studies with experimental animals. Eur J Pharmacol 1990; 180:49-58.
49. Mignot E, Nishino S, Guilleminault C, et al. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994; 17:436-437.
50. Simon P, Hemet C, Ramassamy C, et al. Non-amphetaminic mechanisms of stimulant locomotor effect of modafinil in mice. Eur Neuropsychopharmacol 1995; 5:509-514.
51. Gallopin T, Luppi PH, Rambert FA, et al. Effect of the wake-promoting agent modafinil on sleep-promoting neurons from the ventrolateral preoptic nucleus: an in vitro pharmacologic study. Sleep 2004; 27:19-25.
52. Mignot E, Renaud A, Nishinao S, et al. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology 1993; 113:76-82.
53. Tanganelli S, Fuxe K, Ferraro L, et al. Inhibitory effects of the psychoactive drug modafinil on gamma-aminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea pig. Arch Pharmacol 1992; 345:461-465.
54. U.S. Modafinil in Narcolepsy Multicenter Study Group,. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998; 43:88-97.
55. Edgard DM, Seidel WF. Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. J Pharmacol Exp Ther 1997; 283:757-769.
56. Hermant JF, Rambert FA, Deuteil J. Lack of cardiovascular effects after administration of modafinil in conscious monkeys. Fundam Clin Pharmacol 1991; 5:825.
57. Brun J, Chamba G, Khalfallah Y, et al. Effect of modafinil on plasma melatonin, cortisol and growth hormone rhythms, rectal temperature and performance in healthy subjects during a 36 h sleep deprivation. J Sleep Res 1998; 7:105-114.
58. Gold LH, Balster RH. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology 1996; 126:286-292.
59. Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000; 355:39-40.
60. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998; 92:573-583.
61. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998; 18:9996-10015.
62. Aston-Jones G, Chiang C, Alexinsky T. Discharge of noradrenergic locus coeruleus neurons in behaving rats and monkeys suggests a role in vigilance. Prog Brain Res 1991; 88:501-520.
63. McGinty DJ, Harper R. Dorsal raphe neurons: depression of firing during sleep in cats. Brain Res 1976; 101:569-575.
64. Sakai K, Koyama Y. Are there cholinergic and non-cholinergic paradoxical sleep-on neurons in pons? Neuroreport 1996; 7:2449-2453.
65. Sakai K, Sastre JP, Salvert D, et al. Tegmentoreticular projections with special reference to the muscular atonia during paradoxical sleep in cat: an HRP study. Brain Res 1979; 176:233-254.
66. Kodama T, Lai YY, Siegel JM. Enhancement of acetylcholine release during REM sleep in the caudomedial medulla as measured by in vivo microdialysis. Brain Res 1992; 580:348-350.
67. Vertes RP. Brain stem generation of hippocampal EEG. Prog Neurobiol 1982; 19:159-186.
68. Hobson JA, McCarley RW, Pivik RT, et al. Selective firing by cat pontine brain stem neurons in desynchronized sleep. J Neurophysiol 1974; 37:497-511.
69. Hobson JA, McCarley RW. The brain as a dream state generator: an activation-synthesis hypothesis of the dream process. Am J Psychiatry 1977; 134:1335-1348.
70. Hong CC, Potkin SG, Antrobus JS, et al. REM sleep eye movement counts correlate with visual dream imagery in dreaming: a pilot study. Psychophysiology 1997; 34:377-381.
71. Kilduff TS, Bowersox SS, Kaitin KI, et al. Muscarinic cholinergic receptors and the canine model of narcolepsy. Sleep 1986; 9:102-106.
72. Burrell JM, Black M, Wharton RN, et al. Inhibition of imipramine metabolism by methylphenidate. Fed Proc 1969; 28:418.
73. Carlton PL. Potentiation of the behavioral effects of amphetamines by imipramine. Psychopharmacologia 1961; 2:364-376.
74. Harsh J, Pezka J, Hartwig G, et al. Night-time sleep and daytime sleepiness in narcolepsy. J Sleep Res 2000; 9:309-316.
75. Mamelak M, Black J, Montplaisir J, et al. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 2004; 27:1327-1334.
76. Cook H. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002; 25:42-49.
77. Spillane J, Camejo M. GHB overdoses and deaths in south Florida. In: Community Epidemiology Work Group. Epidemiologic Trends in Drug Abuse. Vol. 2. Rockville: National Institute on Drug Abuse, 1998:432-436. (NIH publication no. 99-4527.)
78. Autret A, Minz M, Beillevaire T, et al. Clinical and polygraphic effects of d.1 5 HTP on narcolepsy-cataplexy. Biomedicine 1977; 27:200-203.
79. Montplaisir J, Godbout R. Serotoninergic reuptake mechanisms in the control of cataplexy. Sleep 1986; 9:280-284.
80. Frey J, Darbonne C. Fluoxetine suppresses human cataplexy: a pilot study. Neurology 1994; 44:707-709.
81. Hublin C, Partinen M, Heinonen EH, et al. Selegiline in the treatment of narcolepsy. Neurology 1994; 44:2095-2101.
82. Reynolds GP, Elsworth JD, Blau K, et al. Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol 1978; 6:542-544.
83. Wallace AG. AN 448 Sandoz (mazindol) in the treatment of obesity. Med J Aust 1976; 1:343.
84. Vespignani H, Barroche G, Escaillas JP, et al. Importance of mazindol in the treatment of narcolepsy. Sleep 1984; 7:274-275.
85. Iijima S, Sugita Y, Teshima Y, et al. Therapeutic effects of mazindol on narcolepsy. Sleep 1986; 9:265-268.
86. Rye DB, Dihenia B, Bliwise DL. Reveral of atypical depression, sleepiness, and REM-sleep propensity in narcolepsy with buproprion. Depress Anxiety 1998; 7:92-95.
87. Afifi AK, Bergman RA. Reticular formation, wakefulness, and sleep: clinical correlates. In: Afifi AK, Bergman RA, eds. Functional Neuroanatomy: Text and Atlas. 2nd ed. New York: McGraw-Hill Medical, 2005:407-410.
88. Huang YS, Guilleminault C, Kao PF, et al. SPECT findings in the Kleine-Levin syndrome. Sleep 2005; 28:955-960.
89. Gill RG, Young JPR, Thomas DJ. Kleine-Levin syndrome. Report of two cases with onset of symptoms precipitated by head trauma. Br J Psychiatry 1988; 152:410-412.
90. Fenzi F, Simonati A, Crosato F, et al. Clinical features of Kleine-Levin syndrome with localized encephalitis. Neuropediatrics 1993; 24(5):292-295.
91. Drake ME. Kleine-Levine syndrome after multiple cerebral infarctions. Psychosomatics 1987; 28:329-333.
92. Dauvilliers Y, Baumann CR, Carlander B, et al. CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry 2003; 74:1667-1673.
93. Chesson AL Jr, Levine SN, Kong LS, et al. Neuroendocrine evaluation in Kleine-Levin syndrome: evidence of reduced dopaminergic tone during periods of hypersomnolence. Sleep 1991; 14(3):226-232.
94. Mayer G, Leonhard E, Krieg J, et al. Endocrinological and polysomnographic findings in KleineLevin syndrome: no evidence for hypothalamic and circadian dysfunction. Sleep 1998; 21:278-284.
95. Poppe M, Friebel D, Reuner U, et al. The Kleine-Levin syndrome: effects of treatment with lithium. Neuropediatrics 2003; 34:113-119.
96. Dauvilliers Y, Mayer G, Lecendreux M, et al. Kleine-Levin syndrome; An autoimmune hypothesis based on clinical and genetic analyses. Neurology 2002; 59:1739-1745.
97. Billiard M, Guilleminault C, Dement, WC. A menstruation-linked periodic hypersomnia. KleineLevin syndrome or new clinical entity? Neurology 1975; 25:436-443.
98. Sachs C, Persson HE, Hagenfeldt K. Menstrual-related periodic hypersomnia: a case study with successful treatment. Neurology 1982; 32:1376-1379.
99. Roth B. On the dissociation of sleep inhibition. Neurol Psychiat Ceskoslov 1954; 17:18-26(in Czech).
100. Poirier G, Montplaisir J, Decary F, et al. HLA antigens in narcolepsy and idiopathic central nervous system hypersomnolence. Sleep 1986; 9:153-158.
101. Roth B, Bruhova s, Lehovsky M. REM sleep and NREM sleep in narcolepsy and hypersomnia. Electroencephalogr Clin Neurophysiol 1969; 26:176-182.
102. Roth B, Nevsimalova S, Rechtschaffen A. Hypersomnia with "sleep drunkenness." Arch Gen Psychiatry 1972; 26:456-462.
103. Bassetti C, Aldrich MS. Idiopathic hypersomnia. A series of 42 patients. Brain 1997; 120:1423-1435.
104. Billiard M, Dauvillier Y. Idiopathic hypersomnia. Sleep Med Rev 2001; 5:351-360.
105. Bassetti C, Pelayo R, Guilleminault C. Idiopathic Hypersomnia. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 4th ed. Philadelphia: Elsevier Saunders, 2005:791-800.
106. Arnulf I, Konofal E, Merino-Andreu M, et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002; 58:1019-1024.
107. Harper DG, Stopa EG, McKee AC, et al. Differential circadian rhythm disturbances in men with Alzheimer disease and frontotemporal degeneration. Arch Gen Psychiatry 2001; 58:353-360.
108. Grace JB, Walker MP, McKeith IG. JA comparison of sleep profiles in patients with dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 2000; 15:1028-1033.
109. Petit D, Montplaisir J, Boeve BF. Alzheimer's disease and other dementias. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 4th ed. Philadelphia: Elsevier Saunders, 2005:853-862.
110. Culebras A. Other neurological disorders. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 4th ed. Philadelphia: Elsevier Saunders, 2005:879-888.
111. Ron S, Algom D, Hary D, et al. Time-related changes in the distribution of sleep stages in brain-injured patients. Electroencephalogr Clin Neurophysiol 1980; 48:432-441.
112. Guilleminault C. Post-traumatic hypersomnia. Course 3AS.007. 52nd Annual Meeting of the American Academy of Neurology, San Diego, California, 2000.
113. Vankova J, Stepanova I, Jech R, et al. Sleep disturbances and hypocretin deficiency in Niemann-Pick disease type C. Sleep 2003; 26:427-430.
114. Martinez-Rodriguez JE, Lin L, Iranzo A, et al. Decreased hypocretin-1(Orexin-A) levels in the cerebrospinal fluid of patients with myotonic dystrophy and excessive daytime sleepiness. Sleep 2003; 26:287-290.
115. Ono S, Takahashi K, Jinnai K, et al. Loss of serotonin-containing neurons in the raphe of patients with myotonic dystrophy: a quantitative immunohistochemical study and relation to hypersomnia. Neurology 1998; 50:535-538.
116. Bassetti CL. Sleep and stroke. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 4th ed. Philadelphia: Elsevier Saunders, 2005:811-830.
117. Bastuji H, Nighoghossian N, Salord F, et al. Mesodiencephalic infarct with hypersomnia: sleep recording in two cases. J Sleep Res 1994; 3(suppl 1):16.
118. Grade C, Redford B, Chrostowski J, et al. Methylphenidate in early poststroke recovery. A doubleblind, placebo-controlled study. Arch Phys Med Rehab 1998; 79:1047-1050.
119. Scheidtmann K, Fries W, Muller F, et al. Effect of levodopa in combination with physiotherapy on functional recovery after stroke: a prospective, randomized, double-blind study. Lancet 2001; 358:787-790.
120. Catsman-Berrevoets CE, Harskamp F. Compulsive pre-sleep behavior and apathy due to bilateral thalamic stroke. Neurology 1988; 38:647-649.
121. Ruiz-Primo E, Jurado JL, Solis H, et al. Polysomnographic effects of thyroid hormones in primary myxedema. Electroencephalogr Clin Neurophysiol 1982; 53:559-564.
122. Morin CM. Psychological and behavioral treatments for primary insomnia. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 4th ed. Philadelphia: Elsevier Saunders, 2005:726-737.
123. Bonnet MH, Balkin TJ, Dinges DF, et al. The use of stimulants to modify performance during sleep loss: a review by the Sleep Deprivation and Stimulant Task Force of the American Academy of Sleep Medicine. Sleep 2005; 28:1163-1187.
124. Jacobs GD. Establishing sleep-promoting habits. In: Brown T, ed. Say Good Night to Insomnia. New York: Henry Holt, 1998:97.
125. Rogers AE, Aldrich MS, Lin X. A comparison of three different sleep schedules for reducing daytime sleepiness in narcolepsy. Sleep 2001; 24:385-391.
126. Achermann P, Werth E, Dijk DJ, et al. Time course of sleep inertia after nighttime and daytime sleep episodes. Arch Ital Biol 1995; 134:109-119.
127. Honda Y, Asaka A, Tanimura M, et al. A genetic study of narcolepsy and excessive daytime sleepiness in 308 families with a narcolepsy or hypersomia proband. In: Guilleminault C, Lugaresi E, eds. Sleep/Wake Disorders: Natural History, Epidemiology, and Long-Term Evolution. New York: Raven Press, 1983:187-198.
128. Guilleminault C, Pelayo R. Idiopathic central nervous system hypersomnia. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia: WB Saunders, 2000:687-692.
129. Terman JS, Terman M, Schlager DS, et al. Efficacy of brief intense light exposure for treatment of winter depression. Arch Gen Psychiatry 1998; 55:875-882.
130. Lam RW, Levitt AJ, eds. Canadian Consensus Guidelines for the Treatment of Seasonal Affective Disorder. Vancouver, British Columbia: Clinical and Academic Publishing, 1999.
131. Glickman G, Hanifin JP, Rollag MD, et al. Inferior retinal light exposure is more effective than superior retinal exposure in suppressing melatonin in humans. J Biol Rhythms 2003; 18:71-79.
132. Terman M, Terman JS. Light therapy. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 4th ed. Philadelphia: Elsevier Saunders, 2005:1424-1442.
133. Tuunainen A, Kripke DF, Endo T. Light therapy for non-seasonal depression. Cochrane Database Syst Rev. 2004;(2):CD004050(review).
134. Gallin PF, Terman M, Reme CE, et al. Ophthalmologic examination of patients with seasonal affective disorder, before and after bright light therapy. Am J Ophthalmol 1995; 119:202-210.
135. Gallin PF, Terman M, Reme DE, et al. The Columbia Eye Examination for Users of Light Treatment. New York: New York State Psychiatric Institute, 1993.
136. Dyken ME, Yamada T. Approach to the patient with sleep disorders. In: Biller J, ed. Practical Neurology. 2nd ed. Philadelphia: Lippincott Williams & Wilkens, 2002:100.
137. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991; 14(6):540-545.
138. Johns MW. Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep 1992; 15:376-381.
139. Chervin RD, Aldrich MS, Pickett R, et al. Comparison of the results of the Epworth Sleepiness Scale and the Multiple Sleep Latency Test. J Psychosom Res 1997; 42:145-155.
140. Johns MW. Sensitivity and specificity of the multiple sleep latency test (MSLT), the Maintenance of Wakefulness Test and the Epworth Sleepiness Scale: failure of the MSLT as a gold standard. J Sleep Res 2000; 9:5-11.
141. A review by the MSLT and MWT Task Force of the Standards of Practice Committee of the American Academy of Sleep Medicine. The clinical use of the MSLT and MWT. Sleep 2005; 28:127-143.
142. Pakola SJ, Dinges DF, Pack AI. Review of regulations and guidelines for commercial and noncommercial drivers with sleep apnea and narcolepsy. Sleep 1995; 18:787-796.
143. Anfield RN. Americans with disabilities Act of 1990. A primer of Title I provisions for occupational health care professionals. J Occup Med 1992; 34:503-509.
144. Federal Aviation Administration (FAA),. Sleep Apnea Evaluation Specifications. Federal Aviation Administration specification letter dated October 6, 1992. Washington, DC: US Department of Transportation; 1992.
145. Mitler MM, Carskadon MA, Hirshkowitz M. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 4th ed. Philadelphia: Elsevier Saunders, 2005:1417-1423.
146. Frolich L. The cholinergic pathology in Alzheimer's disease: discrepancies between clinical experience and pathophysiological findings. J Neural Transm 2002; 109:1003.
147. Angrist B, Sudilovsky A. Central nervous system stimulants: historical aspects and clinical effects. In: Iversen LL, Iversen SD, Snyder SH, eds. Handbook of Psychopharmacology. Vol. 11. New York: Plenum Press, 1976:99-165.
148. National Sleep Foundation,. 2001 "Sleep in America" Poll. Washington, DC: National Sleep Foundation, 2001.
149. Van Dongen HP, Price NJ, Mjllington JM, et al. Caffeine eliminates psychomotor vigilance deficits from sleep inertia. Sleep 2001; 24:813-819.
150. Porkka-Heiskanen T, Strecker RE, Thakkar M, et al. Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. Science 1997; 276:1265-1268.
151. Strecker RE, Morairty S, Thakkar MM, et al. Adenosinergic modulation of basal forebrain and preoptic/anterior hypothalamic neuronal activity in the control of behavioral state. Behav Brain Res 2000; 115:183-204.
152. Mitler MM, O'Malley MB. Wake-promoting medications: efficacy and adverse effects. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 4th ed. Philadelphia: Elsevier Saunders, 2005:484-498.
153. Parkes JD, Dahlitz M. Amphetamine prescription. Sleep 1993; 16:201-202.
154. Wesenten NJ Belenky G, Kautz MA, et al. Maintaining alertness and performance during sleep deprivation: modafinil versus caffeine. Psychopharmacology (Berl) 2002; 159:238-247.
155. Nawrot P, Jordan S, Eastwood J, et al. Effects of caffeine on human health. Food Addit Contam 2003; 20:1-30.
156. Silverman K, Evans SM, Strain EC, et al. Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med 1992; 327:1109-1114.
157. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnia. Arch Neurol 2002; 59:1553-1562.
158. Kubota H, Kanbayashi T, Tanabe Y, et al. A case of acute disseminated encephalomyelitis presenting hypersomnia with decreased hypocretin level in cerebrospinal fluid. J Child Neurol 2002; 17:537-539.
159. Autret A, Lucas B, Mondon K, et al. Sleep and brain lesions: a critical review of the literature and additional new cases. Neurophysiol Clin 2001; 31:356-375.
160. Mieda M, Willie JT, Hara J, et al. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A 2004; 101:4649-4654.
161. Fujiki N, Ripley B, Yoshida Y, et al. Effects of IV and ICV hypocretin-1(orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 2003; 6:953-959.
162. John J, Kumar V, Gopinath G. Recovery of sleep after fetal preoptic transplantation in the medial preoptic area-lesioned rat. Sleep 1998; 21:601-606.
163. Munillo-Rodrigez E, Arias-Carrion O, Xu M, et al. Time course of survival of hypocretin neuronal transplants into the pons of adult rats. Sleep 2004; 27(suppl):A239(abstr).
164. Scammell TE. The neurobiology, diagnosis, and treatment of narcolepsy. Ann Neurol 2003; 53:157-166.
165. Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000; 355:39-40.
166. Nishino S, Sakurai S, Nevisimalova S, et al. CSF histamine content is decreased in hypocretin-deficient human narcolepsy. Sleep 2002; 25(suppl):A476.
167. Shiba T, Fujiki N, Wisor JP, et al. Wake promoting effects of thioperamide, a histamine H3 antagonist in orexin/ataxin-3 narcoleptic mice. Sleep 2004; 27(suppl):A241.
168. Nishino S, Arrigoni J, Kanbayashi T, et al. TRH and its analogs significantly reduce canine cataplexy. Sleep Res 1995; 24A:352.
169. Riehl J, Honda K, Kwan M, et al. Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy. Neuropsychopharmacology 2000; 23:34-45.